Torrado Susana, Roig Meritxell, Farré Magi, Segura Jordi, Ventura Rosa
Institut Municipal d'Investigació Mèdica, Barcelona, Spain.
Rapid Commun Mass Spectrom. 2008 Oct;22(19):3035-42. doi: 10.1002/rcm.3689.
19-Nor-4-androstenediol (NOL) is a prohormone of nandrolone (ND). Both substances are included in the WADA List of Prohibited Classes of Substances and their administration is determined by the presence of 19-norandrosterone (NA) with the urinary threshold concentration of 2 ng mL(-1). Routine analytical procedures allow the determination of NA excreted free and conjugated with glucuronic acid, but amounts of ND and NOL metabolites are also excreted in the sulphate fraction. The aim of this study is to determine the urinary metabolic profile after oral administration of a nutritional supplement containing NOL. Urine samples were collected up to 96 h following supplement administration and were extracted to obtain separately three metabolic fractions: free, glucuronide and sulphate. Extraction with tert-butyl methyl ether was performed after the hydrolysis steps and trimethylsilyl derivatives were analyzed by gas chromatography/mass spectrometry (GC/MS). After oral administration of NOL, the main metabolites detected were NA and noretiocholanolone (NE) in the glucuronide and sulphate fractions. The relative abundances of each metabolite in each fraction fluctuate with time; a few hours after administration the main metabolite was NA glucuronide whereas in the last sample (4 days after administration) the main metabolite was the NA sulphate and the second was the NE glucuronide. During the studied period almost half of the dose was excreted and the main metabolites were still found in urine after 96 h. Norepiandrosterone and norepietiocholanolone were also detected only in the sulphate fraction. Our results suggest that sulphate metabolites should be taken into consideration in order to increase the retrospectivity in the detection of 19-norsteroids after oral administration.
19-去甲-4-雄烯二醇(NOL)是诺龙(ND)的一种激素原。这两种物质均被列入世界反兴奋剂机构的禁用物质类别清单,其使用判定依据是尿中19-去甲雄酮(NA)的存在,尿阈值浓度为2 ng/mL(-1)。常规分析程序可测定游离及与葡萄糖醛酸结合排出的NA,但ND和NOL代谢物的量也会以硫酸盐形式排出。本研究的目的是确定口服含NOL的营养补充剂后的尿液代谢谱。在补充剂给药后长达96小时收集尿液样本,并分别提取以获得三个代谢组分:游离型、葡萄糖醛酸结合型和硫酸盐型。在水解步骤后用叔丁基甲醚进行提取,并用气相色谱/质谱联用仪(GC/MS)分析三甲基硅烷基衍生物。口服NOL后,在葡萄糖醛酸结合型和硫酸盐型组分中检测到的主要代谢物为NA和去氢表雄酮(NE)。每个组分中各代谢物的相对丰度随时间波动;给药后数小时,主要代谢物为NA葡萄糖醛酸结合物,而在最后一个样本(给药后4天)中,主要代谢物为NA硫酸盐,其次为NE葡萄糖醛酸结合物。在研究期间,几乎一半的剂量被排出,96小时后尿液中仍可发现主要代谢物。去甲表雄酮和去甲去氢表雄酮仅在硫酸盐型组分中被检测到。我们的结果表明,为了提高口服给药后19-去甲类固醇检测的追溯性,应考虑硫酸盐代谢物。